K2 Principal Fund, L.P. Genfit S.A. Transaction History
K2 Principal Fund, L.P.
- $285 Million
- Q1 2024
Shares
3 transactions
Others Institutions Holding GNFT
# of Institutions
7Shares Held
76.8KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny29.7KShares$129,5660.0% of portfolio
-
Morgan Stanley New York, NY28.5KShares$124,1030.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il16.8KShares$73,3910.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P7963Shares$4,1980.0% of portfolio
-
Rhumbline Advisers Boston, MA678Shares$2,9560.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $217M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...